Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares surged 120.8% to $0.6450 in pre-market trading after the company reported a new strategic collaboration with Celest Therapeutics for the clinical development of SENTI-301A in China.
With U.S. stock markets set to open in two hours, (DDOG) was up 23.8% in pre-market trading, and (SNOW) was up 7.6%. (CELH), (MDB), and (IFF) were all.